USE OF GALAVIT IN THE COMBINATION TREATMENT OF RECURRENT GENITAL HERPES IN WOMEN

Objective. To evaluate the efficiency of combination therapy for chronic genital herpes infection, by incorporating the immunomodulatory and anti-inflammatory drug galavit in order to stimulate the components of the immune system in patients. Subjects and methods. The study enrolled 30 women aged 19 to 53 years, who had manifestations of chronic recurrent genital herpes. Random sampling was used to form 2 groups: 1) 20 patients receiving basic therapy with valcyclovir (valtrex), 500 mg b.i.d., in combination with 5 daily intramuscular injections of 100 mg of galavit, then 15 more injections of 100 mg of this drug on alternate days (a study group); 2) 10 patients receiving only basic therapy with valcyclovir (a control group). Objective studies involving major symptom rating scales and laboratory tests were used before and 3 and 6 days after therapy. Long-term results of treatment were studied. Results. The study (galavit) group showed a significant increase in the count of CD4+ lymphocytes and NK cells to normal values, a rise in the levels of IFN-а and IFN-y, and restoration of the levels and functional activity of the cells (T helper and NK cells) involved in the suppression of virus replication, as reflected in longer remission. Conclusion. The immunomodulatory and anti-inflammatory drug galavit exerts a stabilizing effect on humoral and cellular immunity, resulting in a reduction in the recurrence rate of chronic genital herpesvirus infection in the late period.

genital herpes, acyclovir resistance, chronic recurrent genital herpes infection, galavit in the combination therapy of chronic genital herpes, immunomodulatory effect of galavit in herpes